A case report of pathological complete response in an elderly patient with advanced urothelial carcinoma treated with disitamab vedotin plus toripalimab
Liang Songlin, Liu Yunxun, He Peiyu, Hu Wen, Li Mingyong · 2026
Read A case report of pathological complete response in an elderly patient with advanced urothelial carcinoma treated with disitamab vedotin plus toripalimab by Liang Songlin, Liu Yunxun, He Peiyu, Hu Wen, Li Mingyong (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13508225.txt.
Description
Liang Songlin and four co-authors report an elderly man's bladder-area cancer that vanished after a two-drug treatment, in a 2026 case report. The patient was 79 and had advanced urothelial carcinoma, a cancer of the urinary tract lining. He declined removal of the bladder, a major operation. His tumor showed only low levels of the HER2 marker that one of the drugs targets. The pair combined a drug-carrying antibody with an immune therapy drug, given every three weeks on back-to-back days.
After six rounds, scans showed the tumor had shrunk greatly. A follow-up procedure that sampled the old tumor bed found no cancer cells left, which counts as a complete response. Side effects stayed mild, limited to fatigue and nausea. The authors urge care in reading one case, and call for larger studies to test the pairing and to find markers that predict who benefits.
Catalog record
| CREATOR | Liang Songlin, Liu Yunxun, He Peiyu, Hu Wen, Li Mingyong |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17008 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |